Clozapine Best Choice for Reducing SUD Risk in Schizophrenia?

Clozapine or antipsychotic polytherapy appear to be the best approach in reducing the risk for a substance use disorder (SUD) in adults with schizophrenia and for preventing relapse in patients with both diagnoses, results of a real-world study show. “Our findings are in line with a recent meta-analysis showing superior efficacy of clozapine in schizophrenia … Read more

Positive Phase 3 Results for Novel Schizophrenia Drug

The investigational agent xanomeline-trospium (KarXT, Karuna Therapeutics), which combines a muscarinic receptor agonist with an anticholinergic agent, helps improve psychosis symptoms, and is not associated with weight gain or sedation in adults with schizophrenia, new research shows. Top-line results from the phase 3 EMERGENT-2 trial showed a significantly greater reduction from baseline on Positive and … Read more

Best Strategy to Prevent Schizophrenia Relapse Identified?

A large meta-analysis sheds light on the best antipsychotic maintenance strategy to prevent relapse in clinically-stable schizophrenia — with some unexpected results that have potential implications for changes to current guidelines. Consistent with the researchers’ hypothesis, continuing antipsychotic treatment at the standard dose, switching to another antipsychotic, and reducing the dose were all significantly more … Read more

Brief Intervention Effective, Durable for Schizophrenia

Metacognitive training (MCT) is effective in reducing positive and negative symptoms of schizophrenia, new research suggests. MCT for psychosis is a brief intervention that “combines psychoeducation, cognitive bias modification, and strategy teaching but does not directly target psychosis symptoms.” Results from a meta-analysis of 40 studies with more than 1,800 total participants with schizophrenia showed … Read more